Jefferies and Deutsche Bank Lower Price Targets on Kenvue (KVUE)

Group 1 - Kenvue Inc. (NYSE:KVUE) is identified as one of the 10 Stocks Under $20 to Buy according to analysts [1] - Jefferies has reduced its price target for Kenvue from $25 to $23, citing signs of weakness in retail trends, with a 1.5% drop representing a 100 basis point reduction quarter-over-quarter [1][2] - Deutsche Bank also lowered its price target from $20 to $18 while maintaining a Hold rating [3] Group 2 - Jefferies believes that Kenvue's guidance for 2025 will remain intact despite the lowered price target due to liability risks [2] - The company is facing legal challenges in the UK related to allegations that its talc products cause cancer [1] - Kenvue Inc. is a global consumer health company with well-known brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol [3]